CTIM-27. PHASE I/II STUDY OF CONTROLLED IL-12 AS IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

DIPG, which is the leading cause of pediatric brain cancer death with no effective treatment, has neither a highly immunosuppressive nor inflammatory tumor microenvironment (TME). Therefore, eliciting a pro-inflammatory TME may provide therapeutic benefit. We previously demonstrated in adults with r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Goldman, Stewart, Mueller, Sabine, Chi, Susan, Saratsis, Amanda, Allen, Rudy, Buck, Jill, Demars, Nathan, Hadar, Nira, Estupinan, Taylor, Miao, John, Walsh, Erin, Gelb, Arnold, Cooper, Laurence
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650466/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.161
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars